NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its third quarter revenues rose 18 percent, driven by the company's molecular business, which now includes Nanosphere.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $71.2 million, up from $60.6 million in the year-ago quarter, and beating the average Wall Street estimate for revenues of $68.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.